COVID19 alert Do we know our enemy?
More details
Hide details
Department of Respiratory Medicine, University General Hospital of Heraklion, Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, Heraklion, Crete, Greece
Interstitial Lung Disease Unit Royal Brompton Hospital, London, United Kingdom
Athens Medical Center and 1st Department of Respiratory Medicine, "Sotiria" Hospital for Diseases of the Chest, National and Kapodistrian University of Athens, Greece
Pneumon 2020;33(1):25–27
SARS-coronavirus 2 (SARS-CoV-2), the etiologic agent of the new lung disease COVID-19 is closely related to SARS-CoV, and together with MERS-CoV are three new human coronaviruses that emerged in the last 20 years. Clinical presentations range from asymptomatic or mild symptoms to severe illness. The prevalent cause of mortality is pneumonia that progresses to ARDS. Such a devastating health burden worldwide has imposed intensive international scientific interest to be focused on the emergence of new therapeutic regimens. Pending the availability of a vaccine, there is a critical need to identify effective treatments and a number of clinical trials have been implemented worldwide. Trials are based on repurposed drugs that are already approved for other infections, have acceptable safety profiles or have performed well in animal studies against the other two deadly coronaviruses. In this review, we summarize the main points of clinical papers published in the current literature employed in epidemiology, clinical trials and intensive care unit (ICU) in COVID-19 disease.
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798):270-3.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323:1061-9.
Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nature Medicine 2020; 26:450-2.
Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017;9(396).
Association of public health interventions with the epidemiology of the covid-19 outbreak in Wuhan, China. JAMA 2020; 323:1-9.
Hartely DM, Perencevich EN. Public health interventions for COVID-19: Emerging evidence and implications for an evolving. Public Health Crisis JAMA 2020; 10.1001/jama.2020.5910.
Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med 2020; NEJMoa2006100.
Launch of SOLIDARITY trial [press release]. WHO, 18 March 2020.
Launch of a European clinical trial against COVID-19 [press release]. INSERM, 22 March 2020.
Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science 2020;367(6485):1412-3.
Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; 323:1574-81.
Cook J, John C Marshall JC, Fowler RA. Critical Illness in Patients With COVID-19: Mounting an Effective Clinical and Research Response JAMA 2020; 10.1001/jama.2020.5775.
Shanafelt T, Ripp J, Trockel M. Understanding and addressing sources of anxiety among health care professionals during the COVID-19 pandemic. JAMA 2020; 10.1001/jama.2020.5893.